Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1998 Nov;82(11):1306–1308. doi: 10.1136/bjo.82.11.1306

Azithromycin for ocular toxoplasmosis

A Rothova 1, L Bosch-Driessen 1, N H van Loon 1, W Treffers 1
PMCID: PMC1722414  PMID: 9924338

Abstract

AIMS—To investigate the efficacy of azithromycin in patients with ocular toxoplasmosis.
METHODS—11 immunocompetent patients with ocular toxoplasmosis were treated with azithromycin (500 mg the first day, followed by 250 mg/day for 5 weeks). Ocular and systemic examinations were performed during active retinitis episodes and all patients were followed for at least 1 year.
RESULTS—The intraocular inflammation disappeared within 4 weeks in seven patients, including two cases with progressive retinitis despite previous treatment with pyrimethamine, sulphadiazine, and folinic acid. Recurrence of retinitis occurred in three patients (27%) within the first year of follow up. No systemic side effects of azithromycin were encountered.
CONCLUSION—These results indicate that although azithromycin cannot prevent recurrent disease it may be an effective alternative for patients with ocular toxoplasmosis who cannot tolerate standard therapies.

 Keywords: azithromycin; ocular toxoplasmosis

Full Text

The Full Text of this article is available as a PDF (83.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ACERS T. E. TOXOPLASMIC RETINOCHOROIDITIS: A DOUBLE BLIND THERAPEUTIC STUDY. Arch Ophthalmol. 1964 Jan;71:58–62. doi: 10.1001/archopht.1964.00970010074010. [DOI] [PubMed] [Google Scholar]
  2. Aarons E., Hawkins D., Nelson M., Gazzard B. Testing and management of Toxoplasma serology in HIV-seropositive patients. AIDS. 1996 Apr;10(4):443–444. doi: 10.1097/00002030-199604000-00015. [DOI] [PubMed] [Google Scholar]
  3. Cochereau-Massin I., LeHoang P., Lautier-Frau M., Zerdoun E., Zazoun L., Robinet M., Marcel P., Girard B., Katlama C., Leport C. Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophthalmol. 1992 Aug 15;114(2):130–135. doi: 10.1016/s0002-9394(14)73975-3. [DOI] [PubMed] [Google Scholar]
  4. Engstrom R. E., Jr, Holland G. N., Nussenblatt R. B., Jabs D. A. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991 May 15;111(5):601–610. doi: 10.1016/s0002-9394(14)73706-7. [DOI] [PubMed] [Google Scholar]
  5. Havlir D. V., Dubé M. P., Sattler F. R., Forthal D. N., Kemper C. A., Dunne M. W., Parenti D. M., Lavelle J. P., White A. C., Jr, Witt M. D. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996 Aug 8;335(6):392–398. doi: 10.1056/NEJM199608083350604. [DOI] [PubMed] [Google Scholar]
  6. Holland G. N., Engstrom R. E., Jr, Glasgow B. J., Berger B. B., Daniels S. A., Sidikaro Y., Harmon J. A., Fischer D. H., Boyer D. S., Rao N. A. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988 Dec 15;106(6):653–667. doi: 10.1016/0002-9394(88)90697-6. [DOI] [PubMed] [Google Scholar]
  7. Huskinson-Mark J., Araujo F. G., Remington J. S. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991 Jul;164(1):170–171. doi: 10.1093/infdis/164.1.170. [DOI] [PubMed] [Google Scholar]
  8. Jacobson M. A., Besch C. L., Child C., Hafner R., Matts J. P., Muth K., Wentworth D. N., Neaton J. D., Abrams D., Rimland D. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Infect Dis. 1994 Feb;169(2):384–394. doi: 10.1093/infdis/169.2.384. [DOI] [PubMed] [Google Scholar]
  9. Jaruratanasirikul S., Hortiwakul R., Tantisarasart T., Phuenpathom N., Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother. 1996 Mar;40(3):825–826. doi: 10.1128/aac.40.3.825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. KAUFMAN H. E. The penetration of daraprim (pyrimethamine) into the monkey eye. Am J Ophthalmol. 1961 Sep;52:402–404. doi: 10.1016/0002-9394(61)90741-3. [DOI] [PubMed] [Google Scholar]
  11. Katlama C., De Wit S., O'Doherty E., Van Glabeke M., Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996 Feb;22(2):268–275. doi: 10.1093/clinids/22.2.268. [DOI] [PubMed] [Google Scholar]
  12. Keusch G. T., Present D. H. Summary of a workshop on clindamycin colitis. J Infect Dis. 1976 May;133(5):578–587. doi: 10.1093/infdis/133.5.578. [DOI] [PubMed] [Google Scholar]
  13. Leport C., Chêne G., Morlat P., Luft B. J., Rousseau F., Pueyo S., Hafner R., Miro J., Aubertin J., Salamon R. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis. 1996 Jan;173(1):91–97. doi: 10.1093/infdis/173.1.91. [DOI] [PubMed] [Google Scholar]
  14. Leport C., Meulemans A., Robine D., Dameron G., Vildé J. L. Levels of pyrimethamine in serum and penetration into brain tissue in humans. AIDS. 1992 Sep;6(9):1040–1041. doi: 10.1097/00002030-199209000-00021. [DOI] [PubMed] [Google Scholar]
  15. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  16. McLeod R., Mack D., Foss R., Boyer K., Withers S., Levin S., Hubbell J. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992 May;36(5):1040–1048. doi: 10.1128/aac.36.5.1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Peacock J. E., Jr, Greven C. M., Cruz J. M., Hurd D. D. Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Bone Marrow Transplant. 1995 Jun;15(6):983–987. [PubMed] [Google Scholar]
  18. Rothova A., Meenken C., Buitenhuis H. J., Brinkman C. J., Baarsma G. S., Boen-Tan T. N., de Jong P. T., Klaassen-Broekema N., Schweitzer C. M., Timmerman Z. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993 Apr 15;115(4):517–523. doi: 10.1016/s0002-9394(14)74456-3. [DOI] [PubMed] [Google Scholar]
  19. Spencer C. M., Goa K. L. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs. 1995 Jul;50(1):176–196. doi: 10.2165/00003495-199550010-00011. [DOI] [PubMed] [Google Scholar]
  20. Weiss L. M., Harris C., Berger M., Tanowitz H. B., Wittner M. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis. 1988 Mar;157(3):580–583. doi: 10.1093/infdis/157.3.580. [DOI] [PubMed] [Google Scholar]
  21. de Boer J. H., Verhagen C., Bruinenberg M., Rothova A., de Jong P. T., Baarsma G. S., Van der Lelij A., Ooyman F. M., Bollemeijer J. G., Derhaag P. J. Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmol. 1996 Jun;121(6):650–658. doi: 10.1016/s0002-9394(14)70631-2. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES